Aurobindo gets FDA nod for diabetes drug

Hyderabad-based Aurobindo Pharma Limited has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Pioglitazone tablets and its earlier tentatively approved Pioglitazone plus Metformin Hydrochloride tablets.

The products are ready for launch, the company said. These products are a generic equivalent of Takeda Global Research Development Center Inc's Actos tablets and are prescribed for treatment of Type II diabetes.

The combined market size of the products was around $ 2.8 billion for the 12-month ending September 2012, the company said. Ranbaxy Laboratories Limited had launched the authorised generic version of Actos in the US in August last year followed by the global generic drug makers Teva and Mylan.